Assertio Therapeutics Approves Key Proposals at Annual Meeting

Assertio Therapeutics ( (ASRT) ) has shared an announcement.

At its recent Annual Meeting, Assertio Therapeutics‘ stockholders approved several key proposals, including an amendment to the 2014 Omnibus Incentive Plan, increasing the number of shares available for issuance by 8,200,000. Additionally, the stockholders elected seven directors to serve until the 2026 Annual Meeting, approved executive compensation, authorized a potential reverse stock split, and ratified Grant Thornton LLP as the independent auditor for 2025. These decisions reflect strategic moves to enhance the company’s operational flexibility and governance structure.

The most recent analyst rating on (ASRT) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.

Spark’s Take on ASRT Stock

According to Spark, TipRanks’ AI Analyst, ASRT is a Neutral.

Assertio Therapeutics’ overall stock score reflects significant challenges in profitability and revenue stabilization, coupled with technical indicators pointing towards a bearish trend. While there are some positive strategic moves and legal settlements, the company’s valuation remains unattractive due to net losses and no dividend yield. Guidance stability offers some reassurance but is overshadowed by operational and financial hurdles.

To see Spark’s full report on ASRT stock, click here.

More about Assertio Therapeutics

Average Trading Volume: 379,495

Technical Sentiment Signal: Sell

Current Market Cap: $58.94M

For an in-depth examination of ASRT stock, go to TipRanks’ Stock Analysis page.